In $23M deal, Syn­cona adds ex-Bio­gen part­ner and 20-year-old gene ther­a­py out­fit AGTC to port­fo­lio

Syn­cona is bring­ing a long-time biotech, with no ap­proved ther­a­pies yet, in­to its fold.

The long­time UK life sci­ences in­vestor, back­ing com­pa­nies such as Force­field …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER